ARCHIVES

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

September 4, 1992

NIH Makes Changes To Area Grants

April 25, 1997

Children’s Cancer Research Institute at UT Health Science Center recruits faculty.

December 10, 2004

AGS-003 Increased Survival In Combination with Sunitinib

February 24, 2012

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

Scientific Community Rallies To Support DeVita; Immediate Suspension Of Straus’ Grant Considered

June 12, 1981